English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

—Migration of vascular smooth muscle cells (VSMC) is a key event in neointimal formation and atherosclerosis that may be linked to the accumulation of inflammatory cells and release of chemotactic cytokines. Tumor necrosis factor-α (TNF-α) induces chemotaxis of inflammatory cells and fibroblasts, but little is known about chemotactic signaling by TNF-α in VSMC. The aim of this study was to investigate the role of TNF-α in VSMC migration and to elucidate the chemotactic signaling pathways mediating this action. TNF-α (50 to 400 U/mL) induced migration of cultured rat aortic VSMC in a dose-dependent manner. Because activation of the extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (MAPK) is known to be required in platelet-derived growth factor–directed and angiotensin II–directed migration of these cells, we used the MAPK-inhibitor PD98059 to determine if chemotactic signaling by TNF-α involves the MAPK pathway as well. We found that TNF-α–directed migration was substantially inhibited by PD98059. TNF-α (100 U/mL) transiently activated MAPK with a maximal induction 10 minutes after stimulation that returned to baseline levels by 2 hours after treatment. Only a single peak of increased MAPK activity was seen. PD98059 also blocked TNF-α–stimulated MAPK activation in a concentration-dependent manner, which is consistent with its inhibition of TNF-α–directed migration. To identify which TNF-α receptor is involved in TNF-α–induced MAPK activation, antibodies against the p55 TNF-α receptor-1 (TNF-R1) and the p75 TNF-α receptor-2 (TNF-R2) were used. VSMC express both receptors, but TNF-α–induced MAPK activation was inhibited only by the TNF-R1 antibody. The TNF-R2 antibody had no effect. Thiazolidinediones are known to inhibit TNF-α signaling in adipose tissue and attenuate platelet-derived growth factor–directed and angiotensin II–directed migration in VSMC. We therefore investigated the effects of the thiazolidinediones troglitazone (TRO) and rosiglitazone (RSG) on TNF-α–induced migration. Both TRO and RSG inhibited migration, but neither attenuated TNF-α–induced MAPK activation, indicating that their antimigration activity was exerted downstream of MAPK. These experiments provide the first evidence that early activation of MAPK is a crucial event in TNF-α–mediated signal transduction leading to VSMC migration. Moreover, inhibition of TNF-α–directed migration by the insulin sensitizers TRO and RSG underscores their potential as vasculoprotective agents.

TNF-α–Induced Migration of Vascular Smooth Muscle Cells Is MAPK Dependent